Rare-disease research often depends on finding another person with a similar phenotype and a variant in the same gene. Sharing data can make that connection possible across institutions and countries. The challenge is to preserve enough information for meaningful comparison while respecting the permissions and protections that accompany sensitive genomic and clinical data.

Illustrated overview of useful data, responsible access, highlighting findability, interoperability, governance.
Useful data, responsible access: findability, interoperability, governance. Read the article for evidence and limitations. Original conceptual illustration.

FAIR does not mean unrestricted

The FAIR principles describe data that are findable, accessible, interoperable and reusable. Accessibility can include authentication and authorization; the principles do not require every dataset to be openly downloadable. Persistent identifiers, rich metadata and clear conditions of use can improve discovery even when the underlying individual-level data require controlled access. Read the original FAIR principles.

For a rare-disease dataset, document the reference assembly, variant representation, phenotype vocabulary, processing methods and version history. Without those details, a nominally available file may be difficult to interpret or impossible to combine reliably with another cohort. Reusability requires scientific context as well as a working download link.

Design governance alongside interoperability

The GA4GH framework for responsible sharing connects scientific benefit with privacy, fairness and accountable oversight. It provides principles for genomic and health-related data sharing rather than a substitute for applicable laws or institutional review. A technically compatible exchange can still be inappropriate if its purpose falls outside the relevant consent or authorization. Read the GA4GH framework.

Consider what each proposed recipient needs to answer the research question. Detailed phenotypes can help match cases but may also make an unusual individual recognizable. Removing names is therefore not the same as eliminating privacy risk. Access decisions should consider the data, the intended use and the protections in the receiving environment.

Make sharing operational

  • Record permitted uses and the process for approving access.
  • Provide a responsible contact for questions, corrections and withdrawal requests.
  • Preserve provenance when data are transformed or combined.
  • Plan how clinically relevant discoveries will be evaluated and, where appropriate, returned.

A useful sharing arrangement specifies responsibilities rather than relying on goodwill alone. Researchers should know what may be redistributed, how errors will be corrected and how contributors receive appropriate recognition. The aim is not maximum exposure of every record; it is a durable route by which authorized researchers can find, understand and responsibly use information that may help solve rare disease.